Related Experiment Video
Updated: Sep 15, 2025
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
Heterogeneous therapy-resistant cancer cells have distinct and exploitable drug sensitivity profiles
Gianna T Busch1, Ryan H Boe2, Jingxin Li2
1Department of Bioengineering, School of Engineering and Applied Sciences University of Pennsylvania, Philadelphia, PA, USA.
Abstract:
Resistance to targeted therapies is a significant clinical problem, but eliminating resistant cancer cells has proven difficult. One potential reason for this difficulty is heterogeneity in the resistant population: even genetically homogeneous cancer cell populations can give rise to many resistant subtypes, each potentially with specific second-line drug vulnerabilities. Using high-throughput drug screening of genetically-identical resistant clones with varying transcriptomes and morphologies, we show that each clone had a distinct drug sensitivity profile. These results suggested that there are drugs that are effective against only subsets of resistant populations but in combination eliminate a large proportion of the resistant population. Using the individual clone sensitivity profiles, we prospectively identified combinations that were highly effective at eliminating most of the resistant population. Our results demonstrate the effectiveness of "subpopulation-directed synergy", showing that considering population heterogeneity can reveal therapeutic opportunities otherwise masked by population averages, offering new strategies to combat therapy resistance.
Insights
Cancer therapy resistance is hard to overcome due to cell heterogeneity. Targeting specific resistant cell subpopulations with drug combinations can eliminate most resistant cells, offering new treatment strategies.
Area of Science:
- Oncology
- Cancer Biology
- Pharmacology
Background:
- Therapy resistance is a major clinical challenge in cancer treatment.
- Heterogeneity within resistant cancer cell populations complicates efforts to eliminate them.
- Genetically similar cancer cells can develop diverse resistant subtypes with unique drug vulnerabilities.
Purpose of the Study:
- To investigate the drug sensitivity profiles of genetically identical but phenotypically diverse resistant cancer cell clones.
- To identify synergistic drug combinations effective against heterogeneous resistant cancer cell populations.
- To demonstrate the therapeutic potential of targeting specific resistant subpopulations.
Main Methods:
- High-throughput drug screening was performed on genetically identical resistant cancer cell clones.
- Clones exhibited varying transcriptomes and morphologies, reflecting heterogeneity.
- Individual clone sensitivity data was used to prospectively identify effective drug combinations.
Main Results:
- Each resistant clone displayed a distinct drug sensitivity profile.
- Certain drugs were effective only against specific resistant subpopulations.
- Identified drug combinations effectively eliminated a large proportion of the diverse resistant cell population.
- Demonstrated 'subpopulation-directed synergy' by leveraging heterogeneity.
Conclusions:
- Cancer cell population heterogeneity presents therapeutic opportunities rather than solely obstacles.
- Considering subpopulation-specific vulnerabilities can reveal synergistic drug combinations.
- This approach offers novel strategies to overcome targeted therapy resistance in cancer.
More Related Videos
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
08:46Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
Related Concept Videos
02:56Treatment Resistant Cancers
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:40Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:53Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...